PFIZER $29.30

up +0.52


22/5/2013 04:22 PM  |  NYSE : PFE  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 30% - PFE has outperformed the S&P 500 by 4%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Odd, This: Big Pharma On Losing End of Pricing Dispute

    YCharts

  2. Biogen Hemophilia Drug News, Upgrades Lift Stock

    Investors Business Daily

  3. OxOnc Announces Deal with Pfizer to Develop Crizotinib as ...

    Benzinga

  4. Why I Want You to Take an Axe to Your Dividend Stock Portfolio

    GuruFocus

  5. Pharma's Pay-to-Delay Deals Face Further Opposition: Senate Bill ...

    YCharts

  6. Huh? After Laying Off 150,000, Big Pharma Says Finding Talent Has ...

    YCharts

  7. Top Mutual Funds Still Nibbling At Ocwen Financial

    Investors Business Daily

  8. Is My Doctor On the Payroll of Some Drug Maker? Now Easier to Find Out

    YCharts

  9. Zoetis Jumps 19% In Debut

    Investors Business Daily

  10. Pay-to-Delay Opponent, FTC Chief Leibowitz, Quits: Respite for Pharma?

    YCharts

  11. Sometime You're a Sap For NOT Buying: Entry Point for Google?

    YCharts

  12. Pfizer's Zoetis Stock Jumps After IPO Prices High

    Investors Business Daily

  13. Zoetis Shares Rise in Market Debut

    FOXBusiness

  14. Pfizer's

    Investors Business Daily

  15. Don't Feel Like a Sap: JPMorgan, After 144% Gain, Still Looks Good

    YCharts

  16. Parexel Stock Falls As Q2, Guidance Worry Analysts

    Investors Business Daily

  17. Are We Saps? Getting In On Pfizer's YTD 7% Gain, But Missing the ...

    YCharts

  18. UPDATE: JP Morgan Raises PT to $31 on Pfizer Following Q4 Results, ...

    Benzinga

  19. Pfizer, Eli Lilly Q4 Beat Views

    Investors Business Daily

  20. Pfizer Stock Hits High On Earnings, Talk Of Split

    Investors Business Daily

  21. S&P 500, Dow Up In Solid Trade, Nasdaq Pares Loss: Pfizer Jumps

    Investors Business Daily

  22. A Weakening Yen Weighs on U.S. Earnings

    FOXBusiness

  23. Pfizer Earnings Beat Consensus; Stock Rises

    Investors Business Daily

  24. UPDATE: Pfizer Posts Upbeat Q4 Results

    Benzinga

  25. Futures Slip as Traders Digest Data, Earnings

    FOXBusiness

  26. Stocks Seek Direction; Data, Earnings in the Spotlight

    FOXBusiness

  27. Pfizer's 4Q Exceeds Views Despite Sinking Sales

    FOXBusiness

  28. Benzinga Market Primer: Tuesday, January 29

    Benzinga

  29. US Stock Futures Slightly Lower Ahead Of Ford Earnings, Consumer ...

    Benzinga

  30. Earnings Scheduled For January 29, 2013

    Benzinga

  31. Stocks To Watch For January 29, 2013

    Benzinga

  32. Zoetis IPO Will Test Market's Appetite For Big Deals

    Investors Business Daily

  33. Pfizer, Lilly Q4 Results Shadowed By Drug Launches

    Investors Business Daily

  34. UPDATE: BMO Capital Markets Raises PT to $30 on Pfizer Ahead of Q4 ...

    Benzinga

  35. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga

  36. Pfizer Wins FDA Approval for Use of Prevnar 13 in Vaccine-Naive ...

    Benzinga

  37. Jobs Data, FOMC Meeting on Tap Next Week

    FOXBusiness

  38. Bright Horizons Soars In IPO, Priced Above Estimate

    Investors Business Daily

  39. Amgen Q4 Sales, 2013 Guidance Modestly Beat Estimates

    Investors Business Daily

  40. Will These 2 IPOs Flourish?

    Benzinga

  41. Pfizer positions animal IPO

    Investors Business Daily

  42. Pfizer Sets Zoetis IPO Terms; Wins Cancer Drug Vote

    Investors Business Daily

  43. FTC: Pay-to-Delay Pharma Deals Cover $8.3 Billion in Revenue

    YCharts

  44. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pfizer

    Benzinga

  45. You Didn't Make That, But: Pfizer Can Be Sued For Injury Caused By ...

    YCharts

  46. Pfizer Says Quillivant XR CII Will Be Available for ...

    Benzinga

  47. Pharma Flop: Story Behind Merck's Failed Cholesterol Pill

    YCharts

  48. Goldman Sachs and Others That May Beat Earnings

    Benzinga

  49. Pfizer Announces EC Approval to Expand Use of Prevenar 13

    Benzinga

  50. 4 Health Care ETFs Your Broker Forgot to Mention

    Benzinga

  51. Do Pharma Stocks Deserve Takeover Premiums? Read This First

    YCharts

  52. Barron's Recap (1/5/12): Low-Risk Income Winners

    Benzinga

  53. Don't Buy Into Wall Street's Rally Too Quickly

    FOXBusiness

  54. The Story Behind Little Halozyme's Seemingly Exciting Hookup With ...

    YCharts

  55. Benzinga Market Primer, Friday, January 4: Non-Farm Payrolls Edition

    Benzinga

  56. Pfizer's Anti-Rheumatoid Arthritis Pill, Potential Blockbuster, ...

    YCharts

  57. Schizo-Well Fargo? Bank Has Two Market Gurus – Two Very Different ...

    YCharts

  58. Pfizer Confirms License of Families of Spinal Muscular Atrophy ...

    Benzinga

  59. Good News For Pharma Stocks: FDA Drug Approval Speedier

    YCharts

  60. Bristol-Myers, Pfizer drug OK'd

    Investors Business Daily

  61. Bristol-Myers, Pfizer Stocks Rise On Eliquis Approval

    Investors Business Daily

  62. Pfizer

    Investors Business Daily

  63. You Can Expect More Insider Trading in Pharma Stocks: Here's Why

    YCharts

  64. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga

  65. Parexel Makes Buyout, Lifts Outlook, But Stock Slips

    Investors Business Daily

  66. Parexel CEO Says 'New Era' For Pharma Has Arrived

    Investors Business Daily

  67. The Best Dogs of the Dow Jones as of December 2012

    GuruFocus

  68. ELIQUIS Receives Approval In Japan for Prevention of Stroke, ...

    Benzinga

  69. Ken Fisher's 3 Highest Yielding Dividend Stocks in Q3

    GuruFocus

  70. This Stock Is Flying High with Another Dividend Increase

    GuruFocus

  71. Barron's Recap (12/22/12): Betting on Europe in 2013

    Benzinga

  72. Failure City: Pharma Eats Up R&D Budgets Trying to Make Drugs to ...

    YCharts

  73. Halozyme Soars After Announcing Deal With Pfizer

    Benzinga

  74. Benzinga's Top Pre-Market Gainers

    Benzinga

  75. Halozyme Therapeutics, Pfizer Collaborate to Develop And ...

    Benzinga

  76. Humedica and Pfizer in Multi-Year Pact

    Benzinga

  77. With Influence Like This, You'd Expect Pharma Stocks to Do Better

    YCharts

  78. Under The Hood: More Defense, More Dividends

    Benzinga

  79. S&P Sees Better 2013 For Health Insurance Providers

    Benzinga

  80. Amgen To Pay $762M To Settle Drug Misbranding Case

    Investors Business Daily

  81. UPDATE: Pfizer Raises Qtr. Dividend from $0.22 to $0.24/Share

    Benzinga

  82. These 2 Dow Laggards Could Rebound in 2013

    Benzinga

  83. Clinical-Trial Flops Hurt AstraZeneca, Lilly, But Bolster Abbott

    YCharts

  84. FDA Accepts NDA for Pfizer, Ligand's Bazedoxifene/Conjugated Estrogens

    Benzinga

  85. UPDATE: JP Morgan Raises PT to $29 on Pfizer Following PD-991 ...

    Benzinga

  86. AstraZeneca, Lilly Arthritis Drugs Flop In Trials

    Investors Business Daily

  87. Lilly Sends Drug Back To Lab

    Investors Business Daily

  88. FDA Says Analysis of Pfizer's Chantix Increased CVE Risk Not ...

    Benzinga

  89. Hemophilia Treatment Could Take A New Leap

    Investors Business Daily

  90. Why Merrill Lynch Strategist Sees S&P 500 Rising 18% in 2013

    YCharts

  91. WebMD to Axe 14% of Workforce

    FOXBusiness

  92. Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)

    Benzinga

  93. There is Life After Patent Expirations: Why Pfizer and Lilly ...

    YCharts

  94. A Look at Fortune's Health Care Picks for 2013 (ALGN, FMS, GILD)

    Benzinga

  95. Bristol-Myers, Pfizer Announce Positive Phase 3 Trial Results for ...

    Benzinga

  96. Barron's Recap (12/8/12): Ten Stock Picks for 2013

    Benzinga

  97. Appeals Court Ruling on Off-Label Drug Marketing: What it Means

    YCharts

  98. How Big Pharma Might Get Its R&D Act Together

    YCharts

  99. If You'd Bought Muni Bonds Shortly After Meredith Whitney's ...

    YCharts

  100. Merck races to beat Lilly debut

    Investors Business Daily
People viewing PFE also viewed: , , , , , ,
Marketplace
Trading Center